Irinotecan (Campto) in the treatment of pancreatic cancer.
about
A multicenter, phase I, dose-escalation study to assess the safety, tolerability, and pharmacokinetics of etirinotecan pegol in patients with refractory solid tumorsCamptothecins in clinical development.A preclinical evaluation of pemetrexed and irinotecan combination as second-line chemotherapy in pancreatic cancerGemcitabine with or without continuous infusion 5-FU in advanced pancreatic cancer: a randomised phase II trial of the Italian oncology group for clinical research (GOIRC).Effect of radiation on the penetration of irinotecan in rat cerebrospinal fluid.
P2860
Irinotecan (Campto) in the treatment of pancreatic cancer.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Irinotecan (Campto) in the treatment of pancreatic cancer.
@ast
Irinotecan (Campto) in the treatment of pancreatic cancer.
@en
type
label
Irinotecan (Campto) in the treatment of pancreatic cancer.
@ast
Irinotecan (Campto) in the treatment of pancreatic cancer.
@en
prefLabel
Irinotecan (Campto) in the treatment of pancreatic cancer.
@ast
Irinotecan (Campto) in the treatment of pancreatic cancer.
@en
P356
P1476
Irinotecan (Campto) in the treatment of pancreatic cancer.
@en
P2093
Joseph F Pizzolato
Leonard B Saltz
P304
P356
10.1586/14737140.3.5.587
P577
2003-10-01T00:00:00Z